Compare SPCE & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCE | CNTN |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.5M | 184.2M |
| IPO Year | 2017 | 2022 |
| Metric | SPCE | CNTN |
|---|---|---|
| Price | $2.92 | $3.04 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $3.26 | N/A |
| AVG Volume (30 Days) | ★ 4.8M | 429.0K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,544,000.00 | N/A |
| Revenue This Year | $2,766.13 | N/A |
| Revenue Next Year | $699.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.13 | $3.07 |
| 52 Week High | $5.59 | $5.27 |
| Indicator | SPCE | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 65.41 | 29.40 |
| Support Level | $2.91 | N/A |
| Resistance Level | $3.42 | $3.51 |
| Average True Range (ATR) | 0.22 | 0.26 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 83.82 | 4.04 |
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.